

MICHAEL H. DAVIDSON, M.D., FACC, FACP, FNLA
Professor of Medicine, Director of the Lipid Clinic
The University of Chicago Pritzker School of Medicine

EDUCATION:

1974 to 1978 Northwestern University
Evanston, IL
Degree: B.A. and M.S. in Biology
Honors: Biology Combined BA/MS Program

MEDICAL SCHOOL:

1978 to 1981 Ohio State University
Columbus, OH
Degree: M.D.
Clerkship Honors - Medicine, Surgery, OB/GYN, Pediatrics

FELLOWSHIP:

1984 to 1986 Rush-Presbyterian-St. Luke's Medical Center
Cardiology
Chicago, IL

RESIDENCY:

1981 to 1984 Rush-Presbyterian-St. Luke's Medical Center
Chicago, IL
Internal Medicine

LICENSURE:

State of Illinois Physician and Surgeon
Number: 036-065126
Expiration Date: July 31, 2017

BOARD CERTIFICATIONS:

2005 American Board of Clinical Lipidology
1987 Cardiology
1984. Internal Medicine

CURRENT POSITIONS:

2007 to present Professor, Director of the Lipid Clinic
The University of Chicago Pritzker School of Medicine

2016 to present Founder and Chief Executive Officer
Corvidia Therapeutics
Waltham, MA

2009 to 2016	Founder and Chief Medical Officer Omthera Pharmaceuticals Bedminster, NJ
2003 to 2011	Executive Medical Director Radiant Research Chicago, IL
October, 2008 April, 2007	Associate Vice Chair for Continuing Medical Education Clinical Professor of Medicine and Director of Preventive Cardiology The University of Chicago Chicago, IL
2001 to 2007	Professor of Medicine and Director of Preventive Cardiology Rush University Medical Center Chicago, IL
1998 to 2003	Executive Medical Director Protocare Trials
1996 to 2003	President & CEO Protocare Trials Chicago Center for Clinical Research Chicago, IL
1986 to 2007	Academic Appointment, Professor Department of Medicine Rush University Medical Center Chicago, IL
1986 to 1996	Founder , CEO and Medical Director Chicago Center for Clinical Research Chicago, IL

Awards

Best Doctors in America
2000-2016
Chicago's Top Doctor's
2000-2016
ADA Father of the Year 2010
NLA's President's Service Award 2012
Expertscape ranks Dr. Davidson # 3 in the world cholesterol expert
State of Israel Bonds Peace Medal

PROFESSIONAL ORGANIZATIONS:

2011 to 2014	American Board of Clinical Lipidology – Board of Directors
2010 to 2011	President of the National Lipid Association
2009 to Present	Program Committee, Atherosclerosis Society Program Committee, American College of Cardiology National Lipid Association – President (2009-2010) National Lipid Association – Fellow (FNLA) The Institute of Medicine of Chicago - Fellow

	Journal of Clinical Lipidology - Associate Editor Current Clinical Pharmacology – Editorial Board
2007 to 2008	American College of Cardiology Program Committee Chairman of the ACC Annual Meeting of the Prevention, Epidemiology and Vascular Biology Section
	Journal of Glycomics & Lipidomics – Editorial Board Journal of Clinical Lipidology - Associate Editor Drug Safety - Editorial Board
2006 to 2008	Midwest Lipid Association - President
	National Lipid Association - Board Member and Chairman of Education Committee
	Council of Arteriosclerosis, Thrombosis and Vascular Biology - Fellow
	Council of Clinical Cardiology - Fellow
1998	American Medical Association Illinois State Medical Society
1991	American College of Cardiology - Fellow
1991	American College of Chest Physicians - Fellow
1986 to 1989	Young Physician Section Delegate
1984 to 1986	Illinois State Medical Society Vice Chairman, Resident Section Chairman, Resident Section
	American College of Physicians - Associate
	Chicago Heart Association
	American Heart Association – Epidemiology - Associate Fellow
1984 to 1985	Alternate Delegate to the House of Delegates State of Illinois Representative
1983 to 1985	American Medical Association Resident Selection Delegate

SCIENTIFIC ADVISORY BOARD MEMBER

Abbott Laboratories
Amgen
AstraZeneca Pharmaceuticals
Merck & Co., Inc.
Sanofi
Regeneron

PATENT/TRADEMARK:

United States Patent Number: 5,279,540 - Michael H. Davidson, M. D., F.A.C.C.
Date of Patent: January 18, 1994.

Abstract: A method for reducing the risk of atherosclerosis in a patient at risk of same comprising the steps of removing cholesterol ester transfer protein from blood of the patient to reduce the plasma CETP levels in the patient. In an embodiment, the method includes the step of passing the patient's plasma through an apheresis machine to remove at least some of the plasma cholesterol ester transfer protein.

BOOKS AND OTHER PUBLICATIONS:

Davidson MH. Lipid Essentials, the what, why, and how of better lipid management. In: Davidson MH, Gleeson R, eds. *Prevent CVD*, 2010.

Davidson MH. Pharmacological therapy for cardiovascular disease: current and emerging therapies. In: Davidson MH, Toth PP, Maki KC, eds. *Therapeutic Lipidology*, Human Press, Inc., 2007.

Davidson MH. Pharmacological therapy for hypertriglyceridemia and low HDL: rationale for combination therapy. In: Braunwald, 2006.

Michael Davidson, M.D., F.A.C.C. The Mobile Lipid Clinic: A Companion Guide. 2nd edition. Lippincott Williams and Wilkins, 2005.

Michael Davidson, M.D., F.A.C.C. The Mobile Lipid Clinic: A Companion Handbook. Lippincott Williams and Wilkins, 2002. (First edition, 80,000 copies sold.)

Michael Davidson, M.D., F.A.C.C. Software Development: Developed the Mobile Lipid Clinic, a Palm OS cardiovascular risk calculation and patient management system for PDA's and the desktop PC. (Over 10,000 copies requested.)

Davidson MH, Robinson JG. Management of elevated low-density lipoprotein cholesterol. In: Gotto AM Jr, Toth PP, eds. *Comprehensive Management of High Risk Cardiovascular Patients*. New York, NY: Informa Healthcare; 2006:255-287.

Davidson MH, Maki KC. Cardiovascular Risk Factors: Evaluation and Treatment Goals. In: Kris-Etherton PM, Burns J (eds). *Cardiovascular Nutrition: Strategies and Tools for Disease Management and Prevention*. Chicago, IL: American Dietetic Association, 1998;3-16.

McDonald A, Maki KC, **Davidson MH.** Management of Dyslipidemia and Hypertension. In: Kris-Etherton PM, Burns J, (eds). *Cardiovascular Nutrition: Strategies and Tools for Disease Management and Prevention*. Chicago, IL: American Dietetic Association, 1998;17-27.

JOURNAL PUBLICATIONS:

1. Narang A, Mor-Avi V, Bhavne NM, Tarroni G, Corsi C, **Davidson MH**, Lang RM, Patel AR. Large high-density lipoprotein particle number is independently associated with microvascular function in patients with well-controlled low-density lipoprotein concentration: A vasodilator stress magnetic resonance perfusion study. *J Clin Lipidol*. 2016 Mar-Apr;10(2):314-22. doi: 10.1016/j.jacl.2015.12.006. Epub 2015 Dec 12.

2. **Davidson MH**, Tomassini JE, Jensen E, Neff D, Polis AB, Tershakovec AM. Time-related trends in variability of cIMT changes in statin trials. *Data Brief*. 2015 Dec 30;6:530-41. doi: 10.1016/j.dib.2015.12.029. eCollection 2016 Mar.
3. **Davidson MH**, Tomassini JE, Jensen E, Neff D, Polis AB, Tershakovec AM. Changing characteristics of statin-related cIMT trials from 1988 to 2006. *Atherosclerosis*. 2016 Mar;246:121-9. doi: 10.1016/j.atherosclerosis.2015.11.023. Epub 2015 Nov 25.
4. Brandt EJ, Regnier SM, Leung EK, Chou SH, Baron BW, Te HS, **Davidson MH**, Sargis RM. Management of lipoprotein X and its complications in a patient with primary sclerosing cholangitis. *Clin Lipidol*. 2015 Aug 1;10(4):305-312.
5. Dunbar RL, Nicholls SJ, Maki KC, Roth EM, Orloff DG, Curcio D, Johnson J, Kling D, **Davidson MH**. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial. *Lipids Health Dis*. 2015 Sep 2;14:98. doi: 10.1186/s12944-015-0100-8.
6. **Davidson MH**. Beta-2 Agonism: A Potential Therapeutic Target for Dyslipidemia. *EBioMedicine*. 2015 Mar 9;2(4):284. doi: 10.1016/j.ebiom.2015.03.004. eCollection 2015 Apr. No abstract available.
7. Castle JW, Kent KP, Fan Y, Wallace KD, Davis CE, Roberts JC, Marino ME, Thomenius KE, Lim HW, Coles E, **Davidson MH**, Feinstein SB, DeMaria A. Therapeutic ultrasound: Increased HDL-Cholesterol following infusions of acoustic microspheres and apolipoprotein A-I plasmids. *Atherosclerosis*. 2015 Jul;241(1):92-9. doi: 10.1016/j.atherosclerosis.2015.04.817. Epub 2015 May 5.
8. Banach M, Rizzo M, Toth PP, Farnier M, **Davidson MH**, Al-Rasadi K, Aronow WS, Athyros V, Djuric DM, Ezhov MV, Greenfield RS, Hovingh GK, Kostner K, Serban C, Lighezan D, Fras Z, Moriarty PM, Muntner P, Goudev A, Ceska R, Nicholls SJ, Broncel M, Nikolic D, Pella D, Puri R, Rysz J, Wong ND, Bajnok L, Jones SR, Ray KK, Mikhailidis DP. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. *Expert Opin Drug Saf*. 2015 Jun;14(6):935-55. doi: 10.1517/14740338.2015.1039980. Epub 2015 Apr 24.
9. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garber JR, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, **Davidson MH**. AACE/Ace comprehensive diabetes management algorithm 2015. *Endocr Pract*. 2015 Apr;21(4):438-47. doi: 10.4158/EP15693.CS. Epub 2015 Apr 15. No abstract available.
10. Banach M, Rizzo M, Toth PP, Farnier M, **Davidson MH**, Al-Rasadi K, Aronow WS, Athyros V, Djuric DM, Ezhov MV, Greenfield RS, Hovingh GK, Kostner K, Serban C, Lighezan D, Fras Z, Moriarty PM, Muntner P, Goudev A, Ceska R, Nicholls SJ, Broncel M, Nikolic D, Pella D, Puri R, Rysz J, Wong ND, Bajnok L, Jones SR, Ray KK, Mikhailidis DP. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. *Arch Med Sci*. 2015 Mar 16;11(1):1-23. doi: 10.5114/aoms.2015.49807. Epub 2015 Mar 14.
11. Rosenson RS, **Davidson MH**, Le NA, Burkle J, Pourfarzib R. Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy. *Cardiovasc Drugs Ther*. 2015 Feb;29(1):41-50. doi: 10.1007/s10557-014-6567-0. Review.
12. Brinton EA, Kher U, Shah S, Cannon CP, **Davidson M**, Gotto AM, Ashraf TB, McCrary Sisk C, Dansky H, Mitchel Y, Barter P; DEFINE Investigators. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP Inhibition with AnacEtrapib) trial. *J Clin Lipidol*. 2015 Jan-Feb;9(1):65-71. doi: 10.1016/j.jacl.2014.10.005. Epub 2014 Nov 4.

13. Rosenson RS, **Davidson MH**, Hirsh BJ, Kathiresan S, Gaudet D. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. *J Am Coll Cardiol*. 2014 Dec 16;64(23):2525-40. doi: 10.1016/j.jacc.2014.09.042. Review.
14. **Davidson MH**, Bechtel DH. Assessment of the effect of esterified propoxylated glycerol (EPG) on the status of fat-soluble vitamins and select water-soluble nutrients following dietary administration to humans for 8 weeks. *Regul Toxicol Pharmacol*. 2014 Dec;70 Suppl 2:S143-57. doi: 10.1016/j.yrtph.2014.11.009. Epub 2014 Dec 8.
15. Nikolic D, Mikhailidis DP, **Davidson MH**, Rizzo M, Banach M. ETC-1002: a future option for lipid disorders? *Atherosclerosis*. 2014 Dec;237(2):705-10. doi: 10.1016/j.atherosclerosis.2014.10.099. Epub 2014 Oct 31. Review.
16. **Davidson MH**, Phillips AK, Kling D, Maki KC. Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia. *Expert Rev Cardiovasc Ther*. 2014 Sep;12(9):1045-54. doi: 10.1586/14779072.2014.942640. Epub 2014 Aug 4. Review.
17. Sponseller CA, Morgan RE, Kryzhanovski VA, Campbell SE, **Davidson MH**. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. *Clin Ther*. 2014 Aug 1;36(8):1211-22. doi: 10.1016/j.clinthera.2014.06.009. Epub 2014 Jul 3.
18. Sampson UK, Harrell FE Jr, Fazio S, Nwosu S, Mercaldo N, Mensah GA, **Davidson MH**, Coll B, Feinstein SB. Carotid adventitial vasa vasorum and intima-media thickness in a primary prevention population. *Echocardiography*. 2015 Feb;32(2):264-70. doi: 10.1111/echo.12646. Epub 2014 Jun 13.
19. **Davidson MH**. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus. *Postgrad Med*. 2014 May;126(3):56-65. doi: 10.3810/pgm.2014.05.2756. Review.
20. Wilkinson MJ, Laffin LJ, **Davidson MH**. Overcoming toxicity and side-effects of lipid-lowering therapies. *Best Pract Res Clin Endocrinol Metab*. 2014 Jun;28(3):439-52. doi: 10.1016/j.beem.2014.01.006. Epub 2014 Jan 23. Review.
21. Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice. Toth PP, Shah PK, Wilkinson MJ, **Davidson MH**, McCullough PA.
22. **Davidson MH**, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Mazzone T, Carlson DM, Williams LA, Kelly MT, Camp HS, Lele A, Stolzenbach JC. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST). *Arterioscler Thromb Vasc Biol*. 2014 Jun;34(6):1298-306. doi: 10.1161/ATVBAHA.113.302926. Epub 2014 Apr 17.
23. Harris WS, **Davidson MH**. RE: Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. *J Natl Cancer Inst*. 2014 Apr;106(4):dju019. doi: 10.1093/jnci/dju019. Epub 2014 Mar 31. No abstract available.
24. STABILITY Investigators, White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, López-Sendón J, Manolis AJ, Mohler ER 3rd, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L. Darapladib for preventing ischemic events in stable

- coronary heart disease. *N Engl J Med*. 2014 May 1;370(18):1702-11. doi: 10.1056/NEJMoa1315878. Epub 2014 Mar 30.
25. Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, **Davidson MH**. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. *J Clin Lipidol*. 2014 Jan-Feb;8(1):94-106. doi: 10.1016/j.jacl.2013.10.003. Epub 2013 Oct 14.
 26. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia—full report. *J Clin Lipidol*. 2014 Jan-Feb;8(1):29-60. doi: 10.1016/j.jacl.2013.12.005. Epub 2013 Dec 17.
 27. Expert Panel on Dyslipidemia. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia: executive summary. *Atherosclerosis*. 2014 Feb;232(2):410-3. doi: 10.1016/j.atherosclerosis.2013.11.031. Epub 2013 Nov 28. Review. No abstract available.
 28. Freed BH, Narang A, Bhave NM, Czobor P, Mor-Avi V, Zaran ER, Turner KM, Cavanaugh KP, Chandra S, Tanaka SM, **Davidson MH**, Lang RM, Patel AR. Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance. *J Cardiovasc Magn Reson*. 2013 Dec 21;15:108. doi: 10.1186/1532-429X-15-108.
 29. Expert Dyslipidemia Panel, Grundy SM. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. *J Clin Lipidol*. 2013 Nov-Dec;7(6):561-5. doi: 10.1016/j.jacl.2013.10.001. Epub 2013 Oct 22. Review.
 30. Wilkinson MJ, **Davidson MH**. Recent developments in the treatment of familial hypercholesterolemia: a review of several new drug classes. *Curr Treat Options Cardiovasc Med*. 2013 Dec;15(6):696-705. doi: 10.1007/s11936-013-0272-3.
 31. **Davidson MH**. Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid. *Curr Opin Lipidol*. 2013 Dec;24(6):467-74. doi: 10.1097/MOL.000000000000019. Review.
 32. IAS Panel for Global Recommendations for the Management of Dyslipidemia, Grundy SM, Arai H, Barter P, Bersot TP, Betteridge DJ, Carmena R, Cuevas A, **Davidson MH**, Genest J, Kesäniemi YA, Sadikot S, Santos RD, Susekov A, Sy R, Tokgozoglul L, Watts GF, Zhao D; International Society of Atherosclerosis. [Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary]. *Clin Investig Arterioscler*. 2014 Jan-Feb;26(1):33-7. doi: 10.1016/j.arteri.2013.09.005. Epub 2013 Oct 26. Spanish.
 33. Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, D'Agostino RB Sr, **Davidson MH**, Davidson WS, Heinecke JW, Karas RH, Kontush A, Krauss RM, Miller M, Rader DJ. High-density lipoproteins: a consensus statement from the National Lipid Association. *J Clin Lipidol*. 2013 Sep-Oct;7(5):484-525. doi: 10.1016/j.jacl.2013.08.001. Epub 2013 Aug 11. Review.
 34. **Davidson MH**, Rooney M, Pollock E, Drucker J, Choy Y. Effect of colessevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose. *J Clin Lipidol*. 2013 Sep-Oct;7(5):423-32. doi: 10.1016/j.jacl.2013.06.001. Epub 2013 Jun 11.
 35. **Davidson MH**, Voogt J, Luchoomun J, Decaris J, Killion S, Boban D, Glass A, Mohammad H, Lu Y, Villegas D, Neese R, Hellerstein M, Neff D, Musliner T, Tomassini JE, Turner S. Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans. *Atherosclerosis*. 2013 Oct;230(2):322-9. doi: 10.1016/j.atherosclerosis.2013.08.006. Epub 2013 Aug 13.

36. **Davidson MH.** Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution. *Nat Rev Cardiol.* 2013 Nov;10(11):618-9. doi: 10.1038/nrcardio.2013.139. Epub 2013 Sep 10. No abstract available.
37. Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, **Davidson MH.** A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). *Clin Ther.* 2013 Sep;35(9):1400-11.e1-3. doi: 10.1016/j.clinthera.2013.07.420. Epub 2013 Aug 30.
38. Garber AJ, Abrahamson MJ, Barzilay JL, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JL, Rosenblit PD, Umpierrez GE, **Davidson MH.** American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. *Endocr Pract.* 2013 May-Jun;19(3):536-57. doi: 10.4158/EP13176.CS. No abstract available.
39. Ballantyne CM, **Davidson MH,** Macdougall DE, Bays HE, Dicarlo LA, Rosenberg NL, Margulies J, Newton RS. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. *J Am Coll Cardiol.* 2013 Sep 24;62(13):1154-62. doi: 10.1016/j.jacc.2013.05.050. Epub 2013 Jun 13.
40. **Davidson MH.** Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction. *J Clin Lipidol.* 2013 May-Jun;7(3 Suppl):S11-5. doi: 10.1016/j.jacl.2013.03.004. Epub 2013 Mar 26.
41. Garber AJ, Abrahamson MJ, Barzilay JL, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JL, Rosenblit PD, Umpierrez G, **Davidson MH;** American Association of Clinical Endocrinologists. AACE comprehensive diabetes management algorithm 2013. *Endocr Pract.* 2013 Mar-Apr;19(2):327-36. No abstract available.
42. Hovingh GK, **Davidson MH,** Kastelein JJ, O'Connor AM. Diagnosis and treatment of familial hypercholesterolaemia. *Eur Heart J.* 2013 Apr;34(13):962-71. doi: 10.1093/eurheartj/ehd015. Epub 2013 Feb 14. Review.
43. Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, Jacobson TA, **Davidson MH.** Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. *J Clin Lipidol.* 2013 Mar-Apr;7(2):102-8. doi: 10.1016/j.jacl.2012.06.006. Epub 2012 Jul 3.
44. **Davidson MH,** Tonstad S, Oparil S, Schwieters M, Day WW, Bowden CH. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥ 27 kg/m². *Am J Cardiol.* 2013 Apr 15;111(8):1131-8. doi: 10.1016/j.amjcard.2012.12.038. Epub 2013 Jan 29.
45. **Davidson MH,** Johnson J, Rooney MW, Kyle ML, Kling DF. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova® compared to Lovaza®) in a pharmacokinetic single-dose evaluation) study. *J Clin Lipidol.* 2012 Nov-Dec;6(6):573-84. doi: 10.1016/j.jacl.2012.01.002. Epub 2012 Jan 24.
46. Roth EM, Rosenson RS, Jones PH, **Davidson MH,** Kelly MT, Setze CM, Lele A, Thakker K. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. *J Clin Lipidol.* 2012 Nov-Dec;6(6):534-44. doi: 10.1016/j.jacl.2012.02.002. Epub 2012 Feb 8.

47. Smith BA, Wright C, **Davidson M**. Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention. *Curr Atheroscler Rep*. 2015 Dec;17(12):72. doi: 10.1007/s11883-015-0550-5. Review.
48. **Davidson MH**. Low-density lipoprotein cholesterol, non-high-density lipoprotein, apolipoprotein, or low-density lipoprotein particle: what should clinicians measure?*. *J Am Coll Cardiol* 2012;60(25):2616-2617.
49. **Davidson MH**. Low-density lipoprotein cholesterol, non-high-density lipoprotein, apolipoprotein, or low-density lipoprotein particle: what should clinicians measure?*. *J Am Coll Cardiol* 2012;60(25):2616-2617.
50. **Davidson MH**. Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: therapeutic approaches to improve outcomes: perspectives of a preventive cardiologist. *Am J Cardiol* 2012 Nov 6;110(9 Suppl):43B-9B.
51. **Davidson MH**. Cardio-diabetes: special considerations for the patient with diabetes and cardiovascular disease. Introduction. *Am J Cardiol* 2012;110(9 Suppl):1B-3B.
52. **Davidson MH**. HDL and CETP Inhibition: Will This DEFINE the Future? *Curr Treat Options Cardiovasc Med* 2012 Aug;14(4):384-90.
53. Toth PP, Ballantyne CM, **Davidson MH**, Tomassini JE, Ramey DR, Neff D, Tershakovec AM, Hu XH, Tunceli K. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. *J Clin Lipidol* 2012;6(2):180-91.
54. Maki KC, Dicklin MR, **Davidson MH**, Mize PD, Kulkarni KR. Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women. *Vasc Health Risk Manag* 2012;8:31-8.
55. Ferdinand KC, Davidson MH, Kelly MT, Setze CM. One-Year Efficacy and Safety of Rosuvastatin+Fenofibric Acid Combination Therapy in Patients with Mixed Dyslipidemia: Evaluation of Dose Response. *Am J Cardiovasc Drugs* 2012;12(2):117-25.
56. Sam S, Haffner S, **Davidson MH**, D'Agostino R Sr, Perez A, Mazzone T. Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes. *J Clin Endocrinol Metab* 2012;97(1):E110-4.
57. Stalenhoef AF, **Davidson MH**, Robinson JG, Burgess T, Duttlinger-Maddux R, Kallend D, Goldberg AC, Bays H. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk. *Diabetes Obes Metab* 2012;14(1):30-39.
58. **Davidson MH**, Kling D, Maki KC. Novel developments in omega-3 fatty acid-based strategies. *Curr Opin Lipidol* 2011;22(6):437-44.
59. Ballantyne CM, **Davidson MH**, Setze CM, Kelly MT. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). *J Clin Lipidol* 2011;5(5):401-7.
60. **Davidson MH**, Ballantyne CM, Jacobson TA, Bittner VA, Braun LT, Brown AS, Brown WV, Cromwell WC, Goldberg RB, McKenney JM, Remaley AT, Snideman AD, Toth PP, Tsimikas S, Ziajka PE, Maki KC, Dicklin MR. Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. *J Clin Lipidol* 2011;5(5):338-67.
61. **Davidson MH**. Stuck between goal achievement and evidence-based medicine. *Curr Cardiol Rep* 2011. [Epub ahead of print].

62. **Davidson MH.** Cardiovascular effects of glucagonlike peptide-1 agonists. *Am J Cardiol* 2011;108(3 Suppl):33B-41B.
63. **Davidson MH,** Plutzky J. The role of cardiologists in the management of patients with diabetes is evolving owing to the close relationship between diabetes and CAD. Introduction. *Am J Cardiol* 2011;108(3 Suppl):1B-2B.
64. **Davidson MH.** Pharmacotherapy: Implications of high-dose statin link with incident diabetes. *Nat Rev Cardiol* 2011; 8(10):543-4.
65. Mangalmurti SS, **Davidson MH.** The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk. *Curr Atheroscler Rep* 2011; 13(5):373-80.
66. Maki KC, **Davidson MH,** Dicklin MR, Bell M, Witchger M, Feinstein SB. Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease. *J Clin Lipidol* 2011;5(3):141-51.
67. Bays HE, **Davidson MH,** Massaad R, Flaim D, Lowe RS, Tershakovec AM, Jones-Burton C. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). *Am J Cardiol* 2011;108(4):523-30.
68. Berger JS, Ballantyne CM, Davidson MH, Johnson JL, Tarka EA, Lawrence D, Trivedi T, Zalewski A, Mohler ER 3rd. Peripheral artery disease, biomarkers, and darapladib. *Am Heart J* 2011;161:972-8.
69. Friedewald VE, Ballantyne CM, **Davidson MH,** Gotto AM Jr, Ridker PM, Roberts WC. The Editor's Roundtable: JUPITER Follow-Up. *Am J Cardiol* 2011;107:1549-57.
70. **Davidson MH.** A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. *J Clin Lipidol.* 2011;5:76-81.
71. **Davidson MH.** Focusing on high-density lipoprotein for coronary heart disease risk reduction. *Cardiol Clin* 2011;29:105-22.
72. **Davidson MH.** Apolipoprotein a-I therapy promise, challenges, and disappointment. *J Am Coll Cardiol.* 2011;57:1120-1.
73. **Davidson MH.** Therapies targeting exogenous cholesterol uptake: new insights and controversies. *Curr Atheroscler Rep* 2011;13:95-100.
74. **Davidson MH.** Update on CETP inhibition. *J Clin Lipidol* 2010;4:394-8.
75. Toth PP, **Davidson MH.** High-density lipoproteins: marker of cardiovascular risk and therapeutic target. *J Clin Lipidol* 2010;4:359-64.
76. **Davidson MH.** Counterpoint: Low-density lipoprotein cholesterol goals in patients with diabetes are adequately based on evidence. *J Clin Lipidol* 2010;4:72-3; discussion 74.
77. Cannon CP, Shah S, Dansky HM, **Davidson M,** Brinton EA, Gotto AM, Stepanavage M, Liu SX, Gibbons P, Ashraf TB, Zafarino J, Mitchel Y, Barter P; Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. *N Engl J Med* 2010;363:2406-15.
78. **Davidson MH,** Donovan JM, Misir S, Jones MR. A 50-week extension study on the safety and efficacy of colessevelam in adults with primary hypercholesterolemia. *Am J Cardiovasc Drugs* 2010;10:305-14.

79. **Davidson MH.** Should niacin be the preferred drug to add to a statin? *Curr Cardiol Rep* 2010;12:447-9.
80. Bakris G, Vassalotti J, Ritz E, Wanner C, Stergiou G, Molitch M, Nesto R, Kaysen GA, Sowers JR; CKD Consensus Working Group. National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. *Kidney Int* 2010;78:726-36.
81. **Davidson MH,** Beam CA, Haffner S, Perez A, D'Agostino R Sr, Mazzone T. Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus. A secondary end point of the CHICAGO study. *Arterioscler Thromb Vasc Biol* 2010;30:1873-6.
82. Maki KC, Dicklin MR, **Davidson MH,** Doyle RT, Ballantyne CM; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. *Am J Cardiol* 2010;105:1409-12.
83. Rosenson RS, **Davidson MH,** Pourfarzib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. *Atherosclerosis* 2010;213:1-7.
84. Braun LT, **Davidson MH.** Lp-PLA2: A new target for statin therapy. *Curr Atheroscler Rep* 2010;12:29-33.
85. Jones PH, Cusi K, **Davidson MH,** Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. *Am J Cardiovasc Drugs* 2010;10:73-84.
86. **Davidson MH,** Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M; LCP-AtorFen Investigators. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. *Clin Ther* 2009;31:2824-38.
87. **Davidson MH.** An urgent matter-identifying your patients' cardiovascular risk and improving their outcomes. Assessing cardiovascular risk one patient at a time. *J Fam Pract* 2009;58(11 Suppl Urgent):S26-31.
88. **Davidson MH,** Rosenson RS. Novel targets that affect high-density lipoprotein metabolism: the next frontier. *Am J Cardiol* 2009;104(10 Suppl):52E-7E.
89. Deedwania P, Singh V, **Davidson MH.** Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials. *Am J Cardiol* 2009;104(10 Suppl):3E-9E.
90. **Davidson MH.** Focus on HDL as a therapeutic target for CAD risk reduction. *Am J Cardiol* 2009;104(10 Suppl):1E-2E.
91. Polis AB, Abate N, Catapano AL, Ballantyne CM, **Davidson MH,** Smugar SS, Tershakovec AM. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. *Metab Syndr Relat Disord* 2009;7:601-10.
92. **Davidson MH.** A Clinical Puzzle: Fibrates and Homocysteine Elevation: Editorial to: "Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al. *Cardiovasc Drugs Ther* 2009;23:341-2..

93. **Davidson MH.** AURORA and JUPITER Trials: Recognizing the limitations and expanding the benefits of statin treatment. *Curr Cardiol Rep* 2009;11:401-3.
94. **Davidson MH,** Maki KC, Bays H, Carter R, Ballantyne CM. Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia. *J Clin Lipidol* 2009;3:332-40.
95. Cannon CP, Dansky HM, **Davidson M,** Gotto AM Jr, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P; DEFINE investigators. Design of the DEFINE trial: determining the Efficacy and tolerability of CETP INhibition with AnacEtrapib. *Am Heart J* 2009;158:513-9.
96. Bairey Merz CN, Alberts MJ, Balady GJ, Ballantyne CM, Berra K, Black HR, Blumenthal RS, **Davidson MH,** Fazio SB, Ferdinand KC, Fine LJ, Fonseca V, Franklin BA, McBride PE, Mensah GA, Merli GJ, O'Gara PT, Thompson PD, Underberg JA; American College of Cardiology Foundation; American Heart Association; American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease); American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; National Lipid Association; Preventive Cardiovascular Nurses Association. ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease. *J Am Coll Cardiol* 2009;54:1336-63.
97. WRITING COMMITTEE MEMBERS, Bairey Merz CN, Alberts MJ, Balady GJ, Ballantyne CM, Berra K, Black HR, Blumenthal RS, **Davidson MH,** Fazio SB, Ferdinand KC, Fine LJ, Fonseca V, Franklin BA, McBride PE, Mensah GA, Merli GJ, O'Gara PT, Thompson PD, Underberg JA. ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease): developed in collaboration with the American Academy of Neurology; American Association of Cardiovascular and Pulmonary Rehabilitation; American College of Preventive Medicine; American College of Sports Medicine; American Diabetes Association; American Society of Hypertension; Association of Black Cardiologists; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute; National Lipid Association; and Preventive Cardiovascular Nurses Association. *Circulation* 2009;120:e100-26.
98. **Davidson MH,** Maki KC, Dicklin MR, Feinsein SB, Witchger M, Bell M, McGuire DK, Provost JC, Liker H, Aviram M. Effects of consumption of pomegranate juice on carotid intima-media thickness in men and women at moderate risk for coronary heart disease. *Am J Cardiol* 2009;104:936-42.
99. **Davidson MH.** Apolipoprotein measurements: is more widespread use clinically indicated? *Clin Cardiol* 2009;32:482-6.
100. Sam S, Haffner S, **Davidson MH,** D'Agostino RB Sr, Feinsein S, Kondos G, Perez A, Mazzone T. Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes. *Diabetes Care* 2009;32:1916-20.
101. **Davidson MH.** Pharmacological Approaches to Modifying HDL: More Basic Science to Understand HDL Metabolism is Necessary : Editorial to: "NO-1886 Up-regulates Niemann-Pick C1 protein (NPC1) expression through Liver X Receptor alpha Signaling Pathway in THP-1 Macrophage-Derived Foam Cells" by Xin Ma et al. *Cardiovasc Drugs Ther* 2009; 23:187-8.

102. Ridker PM, Friedewald VE, **Davidson MH**, Willerson JT, Roberts WC. The editor's roundtable: the JUPITER trial—initial results and clinical implications. *Am J Cardiol* 2009;103:1417-25.
103. Borden WB, **Davidson MH**. Updating the assessment of cardiac risk: beyond Framingham. *Rev Cardiovasc Med* 2009;10:1- 9.
104. Kawata AK, Revicki DA, Thakkar R, Jiang P, Krause S, **Davidson MH**, Punzi HA, Padley RJ. Flushing ASsessment Tool (FAST(c)): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy. *Clin Drug Investig* 2009;29:215-29.
105. Meuwese MC, de Groot E, Duivenvoorden R, Trip MD, Ose L, Maritz FJ, Basart DC, Kastelein JJ, Habib R, **Davidson MH**, Zwindeman AH, Schwocho LR, Stein EA; CAPTIVATE Investigators. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. *JAMA* 2009;301:1131-9.
106. Dembowski E, **Davidson MH**. Statin and ezetimibe combination therapy in cardiovascular disease. *Curr Opin Endocrinol Diabetes Obes* 2009;16:183-8.
107. Sam S, Haffner S, **Davidson MH**, D'Agostino RB Sr, Feinstein S, Kondos G, Perez A, Mazzone T. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. *Diabetes Care* 2009;32:932-7.
108. Koren MJ, **Davidson MH**, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP; ALLIANCE Investigators. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. *Am J Kidney Dis* 2009;53(5):741-50.
109. Dembowski E, **Davidson MH**. A review of lipid management in primary and secondary prevention. *J Cardiopulm Rehabil Prev* 2009;29:2-12.
110. **Davidson MH**, Gandhi SK, Ohsfeldt RL, Fox KM. Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice. *Am J Med* 2009;122(1 Suppl):S51-9.
111. **Davidson MH**. Novel nonstatin strategies to lower low-density lipoprotein cholesterol. *Curr Atheroscler Rep* 2009;11:67-70.
112. **Davidson MH**. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. *Am J Cardiol* 2008;102(suppl):19L-27L.
113. Jones PH, **Davidson MH**, Kashyap ML, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study. *Atherosclerosis* 2008;204(1):208-15..
114. **Davidson MH**, Dembowski E. Atherosclerosis surrogate imaging trials come of age: for better or for worse? *Curr Cardiol Rep* 2008;6:521-5.
115. **Davidson MH**. METEOR and ENHANCE: a tale of two CIMT trials: part 2. *Curr Cardiol Rep* 2008;6:479-80.
116. **Davidson MH**. METEOR and ENHANCE: a tale of two CIMT trials: part 1. *Curr Cardiol Rep* 2008;6:479.
117. Jones PH, Bays HE, **Davidson MH**, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. *Clin Drug Investig* 2008;28:625-34.

118. **Davidson MH**, Jones PH. Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet. *Clin Drug Investig* 2008;28:615-23.
119. Friedewald VE Jr, Ballantyne CM, **Davidson MH**, Guyton JR, Roberts WC. The editor's roundtable: lipid management beyond statins-reducing residual cardiovascular risk. *Am J Cardiol* 2008;102:559-67.
120. Dembowski E, **Davidson MH**. Should every patient with diabetes receive a statin? *Pol Arch Med Wewn* 2008;118:398-401.
121. Musunuru K, Kral BG, Blumenthal RS, Fuster V, Campbell CY, Gluckman TJ, Lange RA, Topol EJ, Willerson JT, Desai MY, **Davidson MH**, Mora S. The use of high-sensitivity assays for C-reactive protein in clinical practice. *Nat Clin Pract Cardiovasc Med* 2008;10:621-35.
122. **Davidson, MH**. Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and apoB in CHD risk assessment. *Arterioscler Thromb Vasc Biol* 2008;28:1582-3.
123. **Davidson, MH**. Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications. *Clev Clin J Med* 2008; 75:479-91.
124. Robinson JG, **Davidson M**. Is it over for ezetimibe? *Expert Rev Cardiovasc Ther* 2008;6:781-3.
125. **Davidson MH**, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, Lerman A, McConnell JP, Weintraub HS. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. *Am J Cardiol* 2008;101(12A):51F-57F.
126. Corson MA, Jones PH, **Davidson MH**. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. *Am J Cardiol* 2008;101(12A):41F-50F.
127. **Davidson MH**. Introduction. U.S. incidence of coronary artery disease. *Am J Cardiol* 2008;101(12A):1F-2F.
128. Polonsky TS, **Davidson MH**. Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. *Am J Cardiol* 2008;101(8A):27B-35B.
129. **Davidson MH**. Niacin use and cutaneous flushing: mechanisms and strategies for prevention. *Am J Cardiol* 2008;101(8A):14B-19B.
130. **Davidson MH**, Ballantyne CM. Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction. *Am J Cardiol* 2008;101(8A):1B-2B.
131. **Davidson M**, Meyer PM, Haffner S, Feinstein S, D'Agostino R Sr, Kondos GT, Perez A, Chen Z, Mazzone T. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. *Circulation* 2008;117:2123-30.
132. Brunzell JD, **Davidson M**, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. *J Am Coll Cardiol* 2008;51:1512-24.
133. Brunzell JD, **Davidson M**, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL; American Diabetes Association; American College of Cardiology Foundation. Lipoprotein management in

- patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. *Diabetes Care* 2008;31:811-22.
134. Ballantyne CM, **Davidson MH**, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I Study). *Am J Cardiol* 2008;101:1428-36.
 135. Sam S, Haffner S, **Davidson MH**, D'Agostino RB, Feinstein S, Kondos G, Perez A, Mazzone T. Relationship of Abdominal Visceral and Subcutaneous Adipose Tissue to Lipoprotein Particle Number and Size in Type 2 Diabetes. *Diabetes* 2008, 57:2022-7.
 136. Toth PP, **Davidson MH**. High-dose statin therapy: benefits and safety in aggressive lipid lowering. *J Fam Pract* 2008;S1-S8.
 137. Mohler ER 3rd, Ballantyne CM, **Davidson MH**, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A; Darapladib Investigators. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. *J Am Coll Cardiol* 2008;51:1632-41.
 138. Skulas-Ray AC, West SG, **Davidson MH**, Kris-Etherton PM. Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. *Expert Opin Pharmacother* 2008;9:1237-48.
 139. Karas RH, Kashyap ML, Knopp RH, Keller LH, Bajorunas DR, **Davidson MH**. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: The OCEANS Study. *Am J Cardiovasc Drugs* 2008;8:69-81.
 140. Stein JH, Tzou WS, Decara JM, Hirsch AT, Mohler ER 3rd, Ouyang P, Pearce GL, **Davidson MH**. Usefulness of Increased Skin Cholesterol to Identify Individuals at Increased Cardiovascular Risk (from the Predictor of Advanced Subclinical Atherosclerosis Study). *Am J Cardiol* 2008;101:986-91.
 141. Bays HE, Tighe AP, Sadovsky R, **Davidson MH**. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. *Expert Rev Cardiovasc Ther* 2008;6:391-409.
 142. Harris WS, Miller M, Tighe AP, **Davidson MH**, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. *Atherosclerosis* 2008;197:12-24.
 143. Maki KC, **Davidson MH**, Witchger MS, Dicklin MR, Subbaiah PV. Effects of high-fiber oat and wheat cereals on postprandial glucose and lipid responses in healthy men. *Int J Vitam Nutr Res* 2007;77:347-56.
 144. Robinson JG, **Davidson MH**. Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport. *Future Lipidol* 2007;2:285-301.
 145. Fox KM, Gandhi SK, Ohsfeldt RL, **Davidson MH**. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. *Am J Manag Care* 2007;13 Suppl 10:S270-5. Review.
 146. **Davidson MH**. Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors. *Am J Manag Care* 2007;13 Suppl 10:S260-9. Review.
 147. **Davidson MH**, Toth PP. Introduction. *Am J Cardiol* 2007;100(11A):S1-2.
 148. **Davidson MH**, Toth PP. High-density lipoprotein metabolism: potential therapeutic targets. *Am J Cardiol* 2007;100(11 A):n32-40.

149. Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto JW, **Davidson MH**. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database. *Clin Ther* 2007;29:2385-94.
150. **Davidson MH**. Targeting high-density lipoprotein cholesterol in the management of cardiovascular disease. *Am Heart Hosp J* 2007 5:210-6.
151. **Davidson MH**. Rosuvastatin in elderly patients. *Drugs Aging* 2007;24:933-44.
152. **Davidson MH**. The use of colesevlam hydrochloride in the treatment of dyslipidemia: a review. *Expert Opin Pharmacother* 2007;8:2569-78.
153. **Davidson MH**, Basile J, Garber AJ, Phillips RA. Reducing the risk of stroke through appropriate targets and treatments. *Prev Cardiol* 2007;10:215-21.
154. Fox KM, Gandhi SK, Ohsfeldt RL, Blasetto JW, **Davidson MH**. Effectiveness of statins in Medicare-eligible patients and patients < 65 years using clinical practice data. *Int J Clin Pract* 2007;61:1634-42.
155. **Davidson MH**, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. *Clin Ther* 2007;29:1354-67.
156. **Davidson MH**, Robinson JG. Safety of aggressive lipid management. *J Am Coll Cardiol* 2007;49:1753-62.
157. **Davidson MH**, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. *Am J Cardiol* 2007;19;99(6A):3C-18C.
158. Maki KC, Rains TM, Kaden VN, Raneri KR, **Davidson MH**. Effects of a reduced-glycemic-load diet on body weight, body composition, and cardiovascular disease risk markers in overweight and obese adults. *Am J Clin Nutr* 2007;85:724-34.
159. Bartels DW, **Davidson MH**, Gong WC. Type 2 diabetes and cardiovascular disease: reducing the risk. *J Manag Care Pharm* 2007;13(2 Suppl A):S2-15
160. Mazzone T, Meyer PM, Kondos GT, **Davidson MH**, Feinstein SB, D'Agostino RB Sr, Perez A, Haffner SM. Relationship of traditional and nontraditional cardiovascular risk factors to coronary artery calcium in type 2 diabetes. *Diabetes* 2007;56:849-55.
161. **Davidson MH**. Global risk management in patients with type 2 diabetes mellitus. *Am J Cardiol* 2007;19;99(4A):41B-50B.
162. **Davidson MH**. Squalene synthase inhibition: a novel target for the management of dyslipidemia. *Curr Atheroscler Rep* 2007 9:78-80.
163. **Davidson MH**. The FIELD Study and Reduction of Cardiovascular Events in Patients with Diabetes. *Curr Atheroscler Rep* 2007; 9:46.
164. **Davidson MH**. The ASPEN Study and Reduction of Cardiovascular Events in Patients with Diabetes. *Curr Atheroscler Rep* 2007;9:46-7.
165. **Davidson MH**. The PROACTIVE Study and Reduction of Cardiovascular Events in Patients with Diabetes. *Curr Atheroscler Rep* 2007;9:45.

166. **Davidson MH**, Yannicelli HD. New concepts in dyslipidemia in the metabolic syndrome and diabetes. *Metab Syndr Relat Disord* 2006;4:299-314.
167. Feldman T, **Davidson M**, Shah A, Maccubbin D, Meehan A, Zakson M, Tribble D, Veltri E, Mitchel Y. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. *Clin Ther* 2006;28:849-59.
168. **Davidson MH**. Differences between clinical trial efficacy and real-world effectiveness. *Am J Manag Care* 2006;12(15 Suppl):S405-11.
169. Mazzone T, Meyer PM, Feinsein SB, **Davidson MH**, Kondos GT, D'Agostino RB Sr, Perez A, Probst JC, Haffner SM. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. *JAMA* 2006;296:2572-81.
170. Deedwania PC, Maki KC, Dicklin MR, Stone NJ, Ballantyne CM, **Davidson MH**. Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II). *J Cardiometab Syndr* 2006;1:295-300.
171. McKenney JM, **Davidson MH**, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesterol ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. *J Am Coll Cardiol* 2006;48:1782-90.
172. **Davidson MH**, McKenney JM, Shear CL, Revkin JH. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. *J Am Coll Cardiol* 2006:1774-81.
173. Ansell BJ, Fonarow GC, Maki KC, Dicklin MR, Bell M, **Davidson MH**; NEPTUNE II Steering Committee. Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: results of a national survey. *Am Heart J* 2006;152:976-81.
174. **Davidson MH**. Is combined treatment with fenofibrate and ezetimibe safe and efficacious in patients with mixed hyperlipidemia? *Nat Clin Pract Cardiovasc Med* 2006;3:594-5.
175. Catapano AL, **Davidson MH**, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, Tershakovec AM. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. *Curr Med Res Opin* 2006;22:2041-53.
176. Robinson JG, **Davidson MH**. How low to target LDL? *Nat Clin Pract Endocrinol Metab* 2006;2:414-5.
177. **Davidson MH**, Robinson JG. Lipid-lowering effects of statins: a comparative review. *Expert Opin Pharmacother* 2006;7:1701-14.
178. **Davidson MH**. Omega-3 fatty acids and cardiovascular disease reduction. Introduction. *Am J Cardiol* 2006;98(4Suppl1):1-2.
179. **Davidson MH**. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. *Am J Cardiol* 2006;98(4Suppl1):27-33.
180. Robinson JG, **Davidson MH**. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. *Expert Rev Cardiovasc Ther* 2006;4:461-76.

181. **Davidson MH**, Bays HE, Stein E, Maki KC, Shalwitz RA, Doyle R; TRIMS Investigators. Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects. *Clin Cardiol* 2006;29:268-73.
182. Clark LT, Maki KC, Galant R, Maron DJ, Pearson TA, **Davidson MH**. Ethnic differences in achievement of cholesterol treatment goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II. *J Gen Intern Med* 2006;21:320-6.
183. Nissen SE, Tuzcu EM, Brewer HB, Sipahi I, Nicholls SJ, Ganz P, Schoenhagen P, Waters DD, Pepine CJ, Crowe TD, **Davidson MH**, Deanfield JE, Wisniewski LM, Hanyok JJ, Kassalow LM; ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators. Effect of ACAT inhibition on the progression of coronary atherosclerosis. *N Engl J Med* 2006;354:1253-63.
184. Maki KC, **Davidson MH**, Dicklin MR. A comparison of Canadian and American guidelines for lipid management using data from the National Cholesterol Education Program Evaluation Project T Utilizing Novel E-technology (NEPTUNE) II survey. *Can J Cardiol* 2006;22:315-22.
185. **Davidson MH**, Dittakavi V, Bandari A, Davidson DJ, Maki KC, Subbaiah PV. Colesevelam HC1 decreases atherosclerosis and may activate reverse cholesterol transport in cholesterol-fed rabbits. *J Applied Res* 2006;6:4-13.
186. **Davidson MH**, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the adverse event reporting system. *Am J Cardiol* 2006;97(suppl):32C-43C.
187. Cziraky MJ, Willey VJ, McKenney JM, Kamat SA, Fisher MD, Guyton JR, Jacobson TA, **Davidson MH**. Statin safety: an assessment using an administrative claims database. *Am J Cardiol* 2006;97(suppl):61C-8C.
188. McKenney JM, **Davidson MH**, Jacobson TA, Guyton, JR. Final conclusions and recommendations of the National Lipid Association statin safety assessment task force. *Am J Cardiol* 2006;97(suppl):89C-94C.
189. **Davidson MH**. Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. *Expert Opin Drug Saf* 2006;5:145-56.
190. **Davidson MH**, Maccubbin D, Stepanavage M, Strony J, Musliner T. Striated muscle safety of combination (ezetimibe/simvastatin) (Vytorin™). *Am J Cardiol* 2006;97:223-8.
191. Raggi P, **Davidson M**, Callister TQ, Welty FK, Bachmann GA, Hecht H, Rumberger JA. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). *Circulation* 2005;112:563-71.
192. Toth PP, **Davidson MH**. Cholesterol absorption blockade with ezetimibe. *Curr Drug Targets Cardiovasc Haematol Disord* 2005;5:455-62.
193. **Davidson M**. Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation. *Prev Cardiol* 2005;8:244-9.
194. Bays H, McKenney JM, **Davidson M**. Torcetrapib/atorvastatin combination therapy. *Expert Rev Cardiovasc Ther* 2005;3:789-820.
195. Maki KC, Galant R, **Davidson MH**. Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. *Am J Cardiol* 2005;96(9A):59K-64K.

196. Corsini A, Bellosta S, **Davidson MH**. Pharmacokinetic interactions between statins and fibrates. *Am J Cardiol* 2005; 96(9A):44K-49K.
197. **Davidson MH**. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. *Am J Cardiol* 2005;96(9A):3K-13K.
198. McKenney JM, **Davidson MH**, Saponaro J, Thompson PD, Bays HE. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. *J Cardiovasc Pharmacol* 2005;46:594-9.
199. **Davidson MH**. Atorvastatin at 80 mg/d reduced major cardiovascular events more than atorvastatin at 10 mg/d in stable coronary heart disease. *ACP J Club* 2005;143:38.
200. **Davidson MH**, Bays H, Rhyne J, Stein E, Rotenberg K, Doyle R. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study. *Clin Ther* 2005;27:715-27.
201. **Davidson MH**. Management of dyslipidemia in patients with complicated metabolic syndrome. *Am J Cardiol* 2005;96(4A):22E-25E.
202. **Davidson MH**, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, Fonarow GC, Maron DJ, Ansell BJ, Clark LT, Ballantyne CM. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP writing group recommendations. *Am J Cardiol* 2005;96:556-63.
203. Insull W, **Davidson MH**, Kulkarni PM, Siddhanti S, Ciaccia AV, Keech CA. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. *Metabolism* 2005;54:939-46.
204. Maki KC, Van Elswyk ME, McCarthy D, Hess SP, Veith PE, Bell M, Subbaiah P, **Davidson MH**. Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol. *J Am Coll Nutr* 2005;24:189-99.
205. **Davidson MH**. Clinical significance of statin pleiotropic effects: hypotheses versus evidence. *Circulation* 2005;111:2280-1.
206. Toth PP, **Davidson MH**. Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. *Expert Opin Pharmacother* 2005;6:131-9.
207. **Davidson MH**. High-dose statins in acute coronary syndromes. *JAMA*. 2005;293:38.
208. Jones PH, **Davidson MH**. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. *Am J Cardiol* 2005;95:120-2.
209. Subbaiah PV, Sowa JM, **Davidson MH**. Evidence for altered positional specificity of LCAT in vivo: studies with docosahexaenoic acid feeding in humans. *J Lipid Res* 2004;45:2245-51.
210. **Davidson MH**, Ballantyne CM, Kerzner B, Melani L, Sager PT, Lipka L, Strony J, Suresh R, Veltri E; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with statins: randomized, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. *Int J Clin Pract* 2004;58:746-55.
211. **Davidson MH**, Toth PP. Combination therapy in the management of complex dyslipidemias. *Curr Opin Lipidol* 2004;15:423-31.

212. **Davidson MH.** Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. *Expert Opin Drug Saf* 2004;3:547-57.
213. **Davidson MH, Toth PP.** Comparative effects of lipid lowering therapies. *Prog Cardiovasc Dis* 2004;47:73-104.
214. **Davidson MH.** Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome. *Am J Cardiol* 2004;93(suppl):3C-11C.
215. Macioch JE, Katsamakidis CD, Robin J, Liebson PR, Meyer PM, Geohas C, Raichlen JS, **Davidson MH**, Feinstein SB. Effect of contrast enhancement on measurement of carotid artery intimal medial thickness. *Vasc Med* 2004;9:1-6.
216. Toth PP, **Davidson MH.** Therapeutic interventions targeted at the augmentation of reverse cholesterol transport. *Curr Opin Cardiol* 2004;19:374-9.
217. **Davidson MH.** Biologic therapies for dyslipidemia. *Curr Atheroscler Rep* 2004;6:69-72.
218. **Davidson MH, Palmisano J, Wilson H, Liss C, Dicklin MR.** A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20 and 40 mg/d with fluvastatin 20 and 40 mg/d. *Clin Ther* 2003;25:2738-53.
219. **Davidson MH, Ose Leiv, Frohlich J, Scott RS, Dujovne CA, Escobar ID, Bertolami MC, Cihon F, MacCubbin DL, Mercuri M.** Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups. *Clin Cardiol* 2003;26:509-14.
220. **Davidson MH.** Niacin: A powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events. *Curr Atheroscler Rep* 2003;5:418-22.
221. **Davidson MH.** Newer pharmaceutical agents to treat lipid disorders. *Curr Cardiol Rep* 2003;5:463-9.
222. **Davidson MH.** Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia. *J Am Coll Cardiol* 2003;42:398-9. [Letter to the Editor]
223. Maki KC, **Davidson MH, Dicklin MR, Ingram KA, Cyrowski M, Umporowicz DM, Bell M, Elliott JG.** Bioavailability of eicosapentaenoic and docosahexaenoic n-3 polyunsaturated fatty acids in salmon patties compared with capsules. *J Food Sci* 2003;68:761-4.
224. Jones Peter H, **Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW,** for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR[®] trial). *Am J Cardiol* 2003;92:152-60.
225. **Davidson MH, Kurlandsky SB, Kleinpell RM, Maki KC.** Lipid management and the elderly. *Prev Cardiol* 2003;6:128-35.
226. **Davidson MH.** Combination lipid-lowering therapy in diabetes. *Curr Diabetes Rep* 2003;3:263-8.
227. **Davidson MH, Maki K, Umporowicz D, Wheeler A, Rittershaus C, Ryan U.** The safety and immunogenicity of a CETP vaccine in healthy adults. *Atherosclerosis* 2003;169:113-20.

228. Rader DJ, **Davidson MH**, Caplan RJ, Pears JS. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. *Am J Cardiol* 2003;91(5A):20C-23C.
229. Ballantyne CM, Corsini A, **Davidson MH**, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JP, Stain EA. Risk for myopathy with statin therapy in high-risk patients. *Arch Intern Med* 2003;163:553-64.
230. Maki KC, Shinnick F, Seeley MA, Veith PE, Quinn LC, Hallissey PJ, Temer A, **Davidson MH**. Food products containing free tall oil-based phytosterols and oat betaglucan lower serum total and LDL cholesterol in hypercholesterolemic adults. *J Nutr* 2003;133:808-13.
231. **Davidson MH**. Ezetimibe: a novel option for lowering cholesterol. *Expert Rev Cardiovasc Ther* 2003;1:11-21.
232. **Davidson MH**, Geohas CT. Efficacy of over-the-counter nutritional supplements. *Curr Atheroscler Rep* 2003;5:15-21.
233. Isaacsohn J, Hunninghake D, Schrott H, Dujowne CA, Knopp R, Weiss SR, Bays H, Crouse JR III, **Davidson MH**, Keilson LM, McKenney J, Korenman SG, Dobs AS, Stein E, Krauss RM, Maccubbin D, Cho Meehyung, Plotkin DJ, Mitchel YB. Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia. *Clin Cardiol* 2003;26:18-24.
234. Braun LT, **Davidson MH**. Cholesterol-lowering drugs bring benefits to high-risk populations even when LDL is normal. *J Cardiovasc Nurs* 2003;18:44-9.
235. Grady D, Herrington D, Bittner V, Blumenthal R, **Davidson M**, Hlatky M, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N; HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). *JAMA* 2002;288:49-57.
236. **Davidson MH**, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. *J Am Coll Cardiol* 2002;40:2125-34.
237. Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW Jr, McKeever C, Miller SS, **Davidson M**, Bolognese MA, Mulloy AL, Heiden N, Wu M, Kaur A, Lombardi A. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 2002;137:875-83.
238. **Davidson, MH**. Combination therapy for dyslipidemia: safety and regulatory considerations. *Am J Cardiol* 2002;90(suppl):50K-60K.
239. Maki KC, **Davidson MH**, Tsushima R, Matsuo N, Tokimitsu I, Umporowicz DM, Dicklin MR, Foster GS, Ingram KA, Anderson BD, Frost SD, Bell M. Consumption of diacylglycerol oil as part of a reduced-energy diet enhances loss of body weight and fat in comparison with consumption of a triacylglycerol control oil. *Am J Clin Nutr* 2002;76:1230-6.
240. Maki KC, Dicklin MR, Cyrowski MS, Umporowicz DM, Nagata Y, Moon G, Forusz S, **Davidson MH**. Improved calcium absorption from a newly formulated beverage compared with a calcium carbonate tablet. *Nutr Res* 2002;22:1163-76.
241. **Davidson MH**. Unidentified multiple risk factor patients: A missed opportunity for primary CHD prevention. *Fam Pract Recertif* 2002;86:23-32.

242. **Davidson MH.** Controversy surrounding the safety of cerivastatin. *Expert Opin Drug Saf* 2002;1:207-12.
243. **Davidson MH,** Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, Hutchinson H. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. *Am J Cardiol* 2002;89:268-75.
244. **Davidson MH.** Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. *Expert Opin Investig Drugs* 2002;11:125-41.
245. Furberg CD, Vittinghoff E, **Davidson M,** Herrington DM, Simon JA, Wenger NK, Hulley S. Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study. Lessons learned. *Circulation* 2002;105:917-22.
246. **Davidson MH,** Bittner VA, Deedwania PC. Lipid management in elderly patients: clinical challenges and therapeutic strategies. *Ann Long Term Care* 2002;10:21-4.
247. **Davidson MH,** Lukacsko P, Sun JX, Phillips G, Walters E, Serman A, Niecestro R, Friedhoff L. A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin. *Clin Ther* 2002;24:112-25.
248. **Davidson MH.** The National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Guidelines. A look to the future: new treatment guidelines and a perspective on statins. *Am J Med* 2002;112(Suppl)8A:34S-41S.
249. **Davidson MH.** Strategies to improve Adult Treatment Panel III guideline adherence and patient compliance. *Am J Cardiol* 2002;89(suppl):8C-22C.
250. **Davidson MH.** A symposium: National Cholesterol Education Program Adult Treatment Panel III: impact and implementation of the new guidelines. Introduction. *Am J Cardiol* 2002;89:1C-2C.
251. **Davidson MH,** Maki KC, Umporowicz DM, Ingram KA, Dicklin MR, Schaefer E, Lane RW, McNamara JR, Ribabya-Mercado JD, Perrone G, Robins SJ, Franke WC. Safety and tolerability of esterified phytosterols administered in reduced-fat spread and salad dressing to healthy adult men and women. *J Am Coll Nutr* 2001;20:307-19.
252. **Davidson MH,** Toth P, Weiss S, McKenney J, Hunninghake D, Isaacsohn J, Donovan JM, Burke SK. Low-dose combination therapy with colestevlam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. *Clin Cardiol* 2001;24:467-74.
253. Insull W Jr, Toth P, Mullican W, Hunninghake D, Burke S, Donovan JM, **Davidson MH.** Effectiveness of colestevlam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. *Mayo Clin Proc* 2001;76:971-82.
254. Hunninghake D, Insull W, Knopp R, **Davidson M,** Lohrbauer L, Jones P, Kafonek S. Comparison of efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. *Am J Cardiol* 2001;88:635-9.
255. **Davidson MH.** Cardiovascular implications of hormonal therapy. *The Female Patient.* December, 2001:13-9.
256. **Davidson MH.** Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions. *J Cardiovasc Pharmacol Ther* 2001;6:219-29.

257. **Davidson MH**, Maki KC, Karp SK, Ingram KA. Management of hypercholesterolemia in postmenopausal women. *Drugs Aging* 2001;19:169-78.
258. Illingworth DR, Crouse JR 3rd, Hunninghake DB, **Davidson MH**, Escobar ID, Stalenhoef AF, Paragh G, Ma PT, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. *Curr Med Res Opin* 2001;17:43-50.
259. Insull W Jr, Koren M, Davignon J, Sprecher D, Schrott H, Keilson LM, Brown AS, Dujovne CA, **Davidson MH**, McLain R, Heinonen T. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. *Atherosclerosis* 2001;157:137-44.
260. Raggi P, Callister TQ, **Davidson MH**, Welty FK, Bachmann GA, Laskey R, Pittman D, Kafonek S, Scott R. Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: rationale and design of the beyond endorsed lipid lowering with EBT scanning (BELLES) trial. *Am Heart J* 2001;141:722-6.
261. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano JM, Donovan JM, Burke SK, **Davidson MH**. Efficacy and safety of combination simvastatin and colesvelam in patients with primary hypercholesterolemia. *Am J Med* 2001;110:352-60.
262. Dujovne CA, Bays H, **Davidson MH**, Knopp R, Hunninghake DB, Stein EA, Goldberg AC, Jones P, Lipka LJ, Cuffie-Jackson C. Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. *J Clin Pharmacol* 2001;41:70-8.
263. **Davidson MH**, Maki KC, Dicklin MR. Benefits of new, non-systemic lipid lowering agent: the clinician's perspective. *Prev Cardiol* 2001;4:38-9.
264. **Davidson MH**. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. *Drugs* 2001;61:197-206.
265. **Davidson MH**. Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents. *Am J Cardiol* 2001 87:1A-7A.
266. **Davidson MH**. Statin trials in progress: unanswered questions. *Curr Atheroscler Rep* 2001;3:9-13.
267. Maki KC, **Davidson MH**, Umporowicz DM, Schaefer EJ, Dicklin MR, Ingram KA, Chen S, McNamara JR, Gebhart BW, Ribaya-Mercado JD, Perrone G, Robins SJ, Franke WC. Lipid responses to plant sterol-enriched reduced-fat spreads incorporated into a NCEP Step 1 diet. *Am J Clin Nutr* 2001;74:33-43.
268. **Davidson M**, Marwah A, Sawchuk RJ, Maki K, Marwah P, Weeks C, Lardy H. Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers. *Clin Invest Med* 2000;23:300-10.
269. Ose L, **Davidson MH**, Stein EA, Kastelein JJ, Scott RS, Hunninghake DB, Campodonico S, Insull W, Escobar ID, Schrott HG, Stepanavage ME, Wu M, Tate AC, Melino MR, Mercuri M, Mitchel YB. Lipid-altering efficacy and safety of simvastatin 80mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group. *Clin Cardiol* 2000;23:39-46.
270. Maki KC, **Davidson MH**. Lean red meat and lean white meat in the NCEP Step I diet. *Curr Treat Options Cardiovasc Med* 2000;2:7-12.

271. **Davidson MH**, Maki KC, Marx P, Maki AC, Cyrowski MS, Nanavati N, Arce JC. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. *Arch Intern Med* 2000;160:3315-25.
272. **Davidson MH**, Dicklin MR, Maki KC, Kleinpell RM. Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. *Expert Opin Investig Drugs* 2000;9:2663-71.
273. Anderson JW, **Davidson MH**, Blonde L, Brown WV, Howard WJ, Ginsberg H, Allgood LD, Weingand KW. Long-term cholesterol-lowering effects of psyllium as an adjunct to diet therapy in the treatment of hypercholesterolemia. *Am J Clin Nutr* 2000;71:1433-8.
274. Dobs AS, Schrott H, **Davidson MH**, Bays H, Stein EA, Kush D, Wu M, Mitchell Y, Illingworth RD. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. *Metabolism* 2000;49:1234-8.
275. Stein E, Plotkin D, Bays H, **Davidson MH**, Dujovne C, Korenman S, Stepanavage M, Mercuri M. Effect of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. *Am J Cardiol* 2000;86:406-11.
276. Kastelein JJ, Isaacsohn JL, Ose L, Hunninghake DB, Frohlich J, **Davidson MH**, Habib R, Dujovne CA, Crouse JR, Liu M, Melino MR, O'Grady L, Mercuri M, Mitchel YB. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. *Am J Cardiol* 2000;86:221-3.
277. Maki KC, **Davidson MH**, Marx P, Cyrowski MS, Maki A. Association between elevated plasma fibrinogen and the small, dense low-density lipoprotein phenotype among postmenopausal women. *Am J Cardiol* 2000;85:451-6.
278. Maki KC, **Davidson MH**, Torri S, Ingram KA, O'Mullane J, Daggy BP, Albrecht HH. High-molecular-weight hydroxypropylmethylcellulose (HPMC) taken with or between meals has hypocholesterolemic effects in adult men. *J Nutr* 2000;130:1705-10.
279. Hunninghake DB, Maki KC, Kwiterovich PO Jr, **Davidson MH**, Dicklin MR, Kafonek SD. Incorporation of lean red meat into a National Cholesterol Education Program Step I diet: a long-term, randomized clinical trial in free-living persons with hypercholesterolemia. *J Am Coll Nutr* 2000;19:351-60.
280. **Davidson MH**. Does differing metabolism by cytochrome P450 have clinical importance? *Curr Atheroscler Rep* 2000;2:14-9.
281. Maki KC, **Davidson MH**, Cyrowski MS, Maki AC, Marx P. Low-density lipoprotein subclass distribution pattern and adiposity-associated dyslipidemia in postmenopausal women. *J Am Coll Nutr* 2000;19:23-30.
282. Isaacsohn JL, **Davidson MH**, Hunninghake D, Singer R, McLain R, Black DM. Aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE) – rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. *Am J Cardiol* 2000; 86:250-2.
283. **Davidson MH**. Efficacy of antiobesity therapies. *Am J Clin Nutr* 2000;71:844.
284. **Davidson MH**, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, Isaacsohn J, Toth P, Burke SK. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. *Arch Intern Med* 1999;159:1893-1900.
285. Maki KC, **Davidson MH**, Malik KC, Albrecht HH, O'Mullane J, Daggy BP. Cholesterol lowering with high-viscosity hydroxypropylmethylcellulose. *Am J Cardiol* 1999;84:1198-1203.

286. Hays JT, Schroeder DR, Croghan IT, Offord KP, Hurt RD, Wolter TD, Nides MA, **Davidson MH**. Over-the-counter 22 mg nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled and open label trials. *Am J Pub Health* 1999;89:1701-7.
287. **Davidson MH**, Maki KC. Effects of dietary inulin on serum lipids. *J Nutr* 1999;129:1474S-1477S.
288. Knopp RH, Superko HR, **Davidson MH**, Insull W, Dujovne CA, Kwiterovich PO, Zavoral JH, Graham K, O'Connor RR, Edelman DA. Long-term blood cholesterol-lowering effects of a dietary fiber supplement. *Am J Preventive Med* 1999;17:18-23.
289. **Davidson MH**, Hunninghake D, Maki KC, Kwiterovich PO Jr, Kafonek S. Comparison of the effects of lean red meat vs lean white meat on serum lipid levels among free-living persons with hypercholesterolemia: a long-term, randomized clinical trial. *Arch Intern Med* 1999;159:1331-8.
290. Schwartz JL, Chan CC, Mukhopadhyay S, McBride KJ, Jones TM, Adcock S, Moritz C, Hedges J, Grasing K, Dobratz D, Cohen RA, **Davidson MH**, Bachmann KA, Gertz BJ. Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. *Clin Pharmacol Ther* 1999;65:653-60.
291. **Davidson MH**, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. *JAMA* 1999;281:235-42.
292. Stein EA, Illingworth DR, Kwiterovich PO Jr, Liacouras CA, Siimes MA, Jacobson MS, Brewster TG, Hopkins P, **Davidson MH**, Graham K, Arensman F, Knopp RH, Dujovne C, Williams CL, Isaacson JL, Jacobsen CA, Lazkarzewski PM, Ames S, Gormley GJ. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. *JAMA* 1999;281:137-44.
293. Elam MB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, **Davidson MH**, Gordon IL, Bortey EB, Forbes WP. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. *Arterioscler Thromb Vasc Biol* 1998;18:1942-7.
294. Money SR, Herd JA, Isaacsohn JL, **Davidson MH**, Cutler B, Heckman J, Forbes WP. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. *J Vasc Surg* 1998;27:267-75.
295. **Davidson MH**, Epstein M, Burt R, Schaefer C, Whitworth G, McDonald A. Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation. *Arch Fam Med* 1998;7:569-74.
296. **Davidson MH**, Dugan LD, Stocki J, Dicklin MR, Maki KC, Coletta F, Cotter R, McLeod M, Hoersten K. A low-viscosity soluble-fiber fruit juice supplement fails to lower cholesterol in hypercholesterolemic men and women. *J Nutr* 1998;128:1927-32.
297. Stein EA, **Davidson MH**, Dobs AS, Schrott H, Dujovne CA, Bays H, Weiss SR, Melino MR, Stepanavage ME, Mitchel YB. Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. *Am J Cardiol* 1998;82:311-6.
298. Koren MJ, Smith DG, Hunninghake DB, **Davidson MH**, McKenney JM, Weiss SR, Schrott HG, Henley RW Jr, Tresh P, McLain RW, Bakker-Arkema RG, Black DM. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. *Pharmacoeconomics* 1998;14:59-70.
299. **Davidson MH**, Maki KC, Kong JC, Dugan LD, Torri SA, Hall HA, Drennan KB, Anderson SM, Fulgoni VL, Saldanha LG, Olson BH. Long-term effects of consuming foods containing psyllium

- seed husk on serum lipids in subjects with hypercholesterolemia. *Am J Clin Nutr* 1998;67:367-76.
300. **Davidson MH**, Maki KC, Synecki C, Torri SA, Drennan KB. Effects of dietary inulin on serum lipids in men and women with hypercholesterolemia. *Nutr Res* 1998;1:503-17.
301. **Davidson MH**, Maki KC. Conjugate equine estrogens and coronary heart disease risk: serum lipid effects. *Menopause Review* 1998.
302. Knopp RH, Alagona P, **Davidson MH**, Goldberg AC, Kafonek SD, Kashyap M, Sprecher D, Superko HR, Jenkins S, Marcovina S. Equivalent efficacy of a time-release form of Niacin (Niaspan) given once-a-night versus plain Niacin in the management of hyperlipidemia. *Metabolism* 1998;47:1097-1104.
303. Maki KC, Kritsch K, Foley S, Soneru I, **Davidson MH**. Age-dependence of the relationship between adiposity and serum low density lipoprotein cholesterol in men. *J Am Coll Nutr* 1997;16:578-83.
304. **Davidson MH**, Nawrocki JW, Weiss SR, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals. *Am J Cardiol* 1997;80:347-8.
305. **Davidson MH**, Testolin LM, Maki KC, Duvillard S, Drennan KB. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. *Arch Intern Med* 1997;157:1186-92.
306. **Davidson MH**, Maki KC, Kalkowski J, Schaefer EJ, Torri SA, Drennan KB. Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial. *J Am Coll Nutr* 1997;16:236-43.
307. **Davidson MH**, Macariola-Coad JR, McDonald AM, Maki KC, Hall HA. Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. *Am J Cardiol* 1997;80:797-8.
308. **Davidson MH**, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, Black D. Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. *Am J Cardiol* 1997;79:1475-81.
309. Maki KC, Kritsch K, Foley S, Soneru I, **Davidson MH**. Age-dependence of the relationship between adiposity and serum low density lipoprotein cholesterol in men. *J Am Coll Nutr* 1997;16:578-83.
310. **Davidson MH**, Stein EA, Dujovne CA, Hunninghake DB, Weiss SR, Knopp RH, Illingworth DR, Mitchel YB, Melino MR, Zupkis RV, Dobrinska MR, Amin RD, Tobert JA. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. *Am J Cardiol* 1997;79:38-42.
311. Schlagheck TG, Kesler JM, Jones MB, Zorich NL, Dugan LD, **Davidson MH**, Peters JC. Olestra's effect on vitamins D and E in humans can be offset by increasing dietary levels of these vitamins. *J Nutr* 1997;127(Suppl):1666S-1685S.
312. Maki KC, **Davidson MH**, McDonald A, Malik KC. Fiber intake and risk of developing non-insulin-dependent diabetes mellitus. *JAMA* 1997;277:1761-2.
313. Enas EA, Garg A, **Davidson MH**, Nair VM, Huet BA, Yusuf S. Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. *Indian Heart J* 1996;48:343-53.
314. **Davidson MH**, Kong JC, Drennan KB, Story K, Anderson GH. Efficacy of the National Cholesterol Education Program Step I diet. A randomized trial incorporating quick-service foods. *Arch Intern Med* 1996;156:305-12.

315. **Davidson MH**, Dugan LD, Burns JH, Sugimoto D, Story K, Drennan K. A psyllium-enriched cereal for the treatment of hypercholesterolemia in children: a controlled, double-blind, crossover study. *Am J Clin Nutr* 1996;63:96-102.
316. **Davidson MH**. Food additive approvals: risks vs benefits. *Regul Toxicol Pharmacol* 1996;23:S25-S26.
317. Stein EA, **Davidson MH**, Dujovne CA, Hunninghake DB, Goldberg RB, Illingworth R, Knopp RH, Miller VT, Frost P, Isaacsohn JL, Mitchel YB, Melino MR, Shapiro D, Tolbert JA. Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. *J Cardiovasc Pharmacol Ther* 1996;1:107-16.
318. Bakker-Arkema RG, **Davidson MH**, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. *JAMA* 1996;275:128-33.
319. Ashraf T, Hay JW, Pitt B, Wittels EH, Crouso J, **Davidson MH**, Furberg CD, Radican L. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. *Am J Cardiol* 1996;78:409-14.
320. Borzelleca JF, Cheney M, **Davidson MH**, Degnan FH, Derfler PS, Forbes AL, Glinsmann W, Heckman JH, Miller SA, Rulis AM, Masten LW. Panel discussion: what is the future of macronutrient substitutes in North America? *Regul Toxicol Pharmacol* 1996;23:S51-S59.
321. Illingworth DR, Stein EA, Knopp RH, Hunninghake DB, **Davidson MH**, Dujovne CA, Miller VT, Tolbert JA, Laskarzewski PM, Isaacsohn JL, Bacon SP, Tate AC. A randomized multicenter trial comparing the efficacy of simvastatin and fluvastatin. *J Cardiovasc Pharmacol Ther* 1996;1:23-30.
322. Nawrocki JW, Weiss SR, **Davidson MH**, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. *Arterioscler Thromb Vasc Biol* 1995;15:678-82.
323. Schrott HG, Stein EA, Dujovne CA, **Davidson MH**, Goris GB, Oliphant TH, Phillips JC, Shawaryn GG. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose cholesterol plus lovastatin combination therapy. *Am J Cardiol* 1995;75:34-9.
324. Insull W Jr, **Davidson MH**, Demke DM, Dujovne CA, Eckert SM, Ginsberg D, Goldberg AC, Hodis HN, Hughes TA, Kane JP, Oliphant TH. The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients. *Atherosclerosis* 1995;112:223-35.
325. **Davidson MH**. Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safety. *Am J Med* 1994;96:41S-44S.
326. Dujovne CA, **Davidson MH**. Fluvastatin administration at bedtime versus with the evening meal: a multi-center comparison of bio-availability, safety and efficacy. *Am J Med* 1994; 96:37S-40S.
327. Epstein KR, Freedman MA, Gorodeski GI, Wenger NK, **Davidson MH**. Established cardiovascular disease -- does HRT offer benefits? *Menopause Management* 1993;2:10.
328. **Davidson MH**, Rosenson RS, Mazzone T. From diagnosis to treatment: focus on costs, safety, and efficacy of antihyperlipidemic agents. *Hosp Formul* 1993;28:262-82.
329. **Davidson MH**. Antioxidants and lipid metabolism. Implications for the present and direction for the future. *Am J Cardiol* 1993;71:32B-36B.

330. Ripsin CM, Keenan JM, Jacobs DR Jr, Elmer PJ, Welch RR, Horn LV, Liu K, Turnbull WH, Thye FW, Kestin M, Hegsted M, **Davidson MH**, Dugan LD, Demark-Wahnefried W, Beling S. Oat products and lipid lowering: a meta-analysis. *JAMA* 1992;267:3317-25.
331. Dugan LD, Burns J, **Davidson MH**, Synecki C. Exploring the lipid-lowering effects of oats. *J Cardiopulmonary Rehabil* 1992;12:164-6.
332. Bagdade JD, Ritter MC, **Davidson MH**, Subbaiah PV. Effect of marine lipids on cholesteryl ester transfer and lipoprotein composition in patients with hypercholesterolemia. *Arteriosclerosis Thromb* 1992;12:1146-52.
333. **Davidson MH**. Emerging trends in lipid management. *Lipids & Atherogenesis* 1992;2:1-4.
334. Lands WE, Libelt B, Morris A, Kramer NC, Prewitt TE, Bowen P, Schmeiser D, **Davidson MH**, Burns JH. Maintenance of lower proportions of (n-6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n-3) fatty acids. *Biochim Biophys Acta* 1992;1180:147-62.
335. **Davidson MH**. Lipid-lowering agents: current status, future directions. *J Myocard Ischemia* 1991;3:35.
336. **Davidson MH**, Dugan LD, Burns JH, Bova J, Story K, Drennan KB. The hypocholesterolemic effects of beta-glucan in oatmeal and oat bran: a dose-controlled study. *JAMA* 1991;265:1833-9.
337. **Davidson MH**, Burns JH, Subbaiah PV, Conn ME, Drennan KB. Marine oil capsule therapy for the treatment of hyperlipidemia. *Arch Intern Med* 1991;151:1732-40.
338. **Davidson MH**, Gwynne JT, Khachadurian AK, LaRosa JC, Weber MA, Markowitz JS, Behounek BD. Combination of pravastatin and probucol in the treatment of primary hypercholesterolemia. *Curr Science ISSN* 1991;2:1061-8.
339. **Davidson MH**. The hypocholesterolemic effects of b-glucan in oatmeal and oat bran: a dose controlled study. *J Am Coll Cardiol* 1990;15:156A.
340. **Davidson MH**, Bagdade JD, Liebson PR, Subbaiah P, Messer JV, Schoenberger JA. Comparative effects of marine and olive oil dietary supplementation on coronary risk factors. *J Applied Cardiol* 1989;4:145-51.
341. Subbaiah PV, **Davidson MH**, Ritter MC, Buchanan W, Bagdade JD. Effects of dietary supplementation with marine lipid concentrate on the plasma lipoprotein composition of hypercholesterolemic patients. *Atherosclerosis* 1989;79:157-66.
342. **Davidson MH**. Marine oil as a therapy for hyperlipidemia. *Cardiovasc Perspect* 1989;4.
343. **Davidson MH**, Conn M, Preys M, Bagdade JD. 8th 1 ester marine oil capsules to the treatment of type II B hyperlipidemia: a double blind, dose controlled study. *Arteriosclerosis* 1988;8:592a.
344. **Davidson MH**, Liebson PR. Marine lipids and atherosclerosis: a review. *Cardiovasc Rev Rep* 1986;7:461-72.
345. Liebson PR, **Davidson MH**. Mitral valve prolapse: recent advances in diagnosis and therapy. *Compr Ther* 1986;12:21-32.

ABSTRACTS (Selected):

1. Kling DF, Johnson J, Rooney M, **Davidson M**: Omega-3 free fatty acids demonstrate more than 4-fold greater bioavailability for EPA and DHA compared with omega-3-acid ethyl esters in conjunction with a low-fat diet: The ECLIPSE Study. *J Clin Lipidol* 2011;5:231.
2. **Davidson MH**, Maki KC, Dicklin M, Umporowicz DM. Achievement of both the LDL cholesterol and total/HDL cholesterol ratio Canadian guideline goals by US physicians: Results from Neptune II. 2004. Presented at the Canadian Cardiovascular Society 57th Annual Meeting, October 23-27, 2004. *The Canadian Journal of Cardiology* 2004; 20:140D: 378.
2. Maki KC, Bell M, Oldham KM, **Davidson MH**. Is hyperfibrinogenemia a component of the metabolic syndrome? Presented at the American Diabetes Association. December, 2001.
3. **Davidson MH**, Wheeler A, Rittershaus C, Emmett C, Umporowicz D, Maki KC. A phase I trial of an immunotherapeutic approach for managing low plasma HDL-C. Presented at the XIV International Symposium on Drugs Affecting Lipid Metabolism. September, 2001.
4. **Davidson MH**, Lukacsko P, Friedhoff L, Sterman A, Walters E, Sun J, Phillips G. A multi-dose safety, pharmacokinetic and pharmacodynamic study of lovastatin extended-release relative to lovastatin immediate-release. Presented at the XIV International Symposium on Drugs Affecting Lipid Metabolism. September, 2001.
5. **Davidson M**, Scott R, Frohlich J, Cihon F, Kush D, O'Grady L, Vala M, Mitchel Y. Differential effects of simvastatin and atorvastatin on high density lipoprotein cholesterol and apoprotein A-1 in hypercholesterolemic patients: Cohort and subgroup analyses. Presented at the XIV International Symposium on Drugs Affecting Lipid Metabolism. September, 2001.
6. **Davidson MH**, Hutchinson HG, Chitra R, Raza A, Gotto A. ZD4522 is superior to atorvastatin in decreasing LDL-C and increasing HDL-C in patients with type IIa and IIb hypercholesterolemia. Submitted to American College of Cardiology annual meeting.
7. Maki KC, **Davidson MH**, Palmisano J, Susmano A, Dobs A, Kerber I, Hunninghake D, Knopp R, Goldberg A, McKenney J, Kakavas P, Walters D Bittar N. Separate and combined efforts of hormone replacement and simvastatin 10 mg on lipoprotein (a) and lipoprotein subfractions in postmenopausal women with hypercholesterolemia. Submitted to American College of Cardiology annual meeting.
8. Maki KC, **Davidson MH**, Cyrowski M, Maki AC, Marx P. Low density lipoprotein (LDL) subclass pattern B amplifies adiposity-associated dyslipidemia in postmenopausal women. FASEB, 2000.
9. **Davidson MH**, Maki KC, Marx PD, Arce J-C, Nanavati N. Effects of low-dose, continuous combined hormone replacement on serum lipids in postmenopausal women. Presented at the First Conference on Arteriosclerosis, Thrombosis, and Vascular Biology, 2000.
10. Maki KC **Davidson MH**, Marx PD, Cyrowski M, Arce J-C. Effects of continuous hormone replacement therapy on indicators of carbohydrate metabolism. Presented at the American Diabetes Association 60th Scientific Sessions, 2000.
11. Maki KC, **Davidson MH**, Susmano A, Maki AC. Low-density lipoprotein subclass pattern B and adiposity-associated dyslipidemia in postmenopausal women. Presented at the American College of Nutrition annual meeting, 2000.
12. Maki KC, **Davidson MH**, Tsushima R, Matsuo N, Tokimitsu I, Umporowicz D, Ingram KA, Dicklin MR, Bell M, Anderson BD, Frost SD, Tagala A. Diacylglycerol vs soybean oil in a weight reduction diet. Presented at North American Association for the Study of Obesity annual meeting, 2000.
13. **Davidson MH**, Maki KC, Hunninghake DB, Knopp RH, Goldberg RB, Waters D, Dobs AS, Cyrowski M. Effects of Low Dose Simvastatin and Hormone Replacement Therapy on Serum Lipids in

Postmenopausal Women with Hypercholesterolemia. *American College of Cardiology 49th Annual Scientific Session*, 2000.

14. Maki KC, **Davidson MH**, Cyrowski M, Maki AC, Marx P. Adiposity-associated Dyslipidemia in Postmenopausal Women. Submitted for *Experimental Biology* annual meeting, Apr 15-18, 1999.
15. Maki KC, **Davidson MH**, Umporowicz D, Schaefer E, Dicklin MR, Ingram KA, Chen S, Gebhart B, Franke WC. Lipid Responses to Plant Sterol-enriched Reduced-fat Spreads Incorporated into a Step I Diet. *Circulation*. 1999 Nov;100:1115.
16. Maki KC, **Davidson MH**, Umporowicz D, Dicklin MR, Ingram KA, Gebhart B, Schaefer E, Chen S, Franke WC. Effects of Plant Sterol-enriched Reduced-fat Spreads on Serum Carotenoid and Fat-Soluble Vitamin Levels. *J Am Coll Nutr*. 1999 Nov;18:536.
17. Maki KC, **Davidson MH**, Marx P, Cyrowski M, Maki AC. Low Density Lipoprotein Subclass Distribution Pattern Does Not Modify Serum Lipid and Apolipoprotein Responses to Hormone Replacement Therapy. 1999 Oct; Proceedings, *9th International Menopause Society World Congress on the Menopause*.
18. Maki KC, **Davidson MH**, Cyrowski M, Maki AC. Association Between Elevated Plasma Fibrinogen and the Small, Dense Low Density Lipoprotein Phenotype Among Postmenopausal Women. *Circulation*. 1999 Mar 2;99:1124.
19. Rippe J, Bonovich K, Colfer H, **Davidson MH**, Dujovne C, Fried D, Greenspan M, King S, Karlsberg R, LaForce C, Litt M. A Multi-Center, Self-Controlled Study of Cholestin[®] in Subjects with Elevated Cholesterol. *Circulation*. 1999 Mar 2;99:1123.
20. **Davidson MH**, Weeks CE, Lardy H, Maki KC, Umporowicz D. Safety and Endocrine Effects of 3-Acetyl-7-Oxo DHEA. *FASEB*. 1998, Mar 20,12:A764.
21. Heinonen TM, Stein E, Weiss SR, McKenney JM, **Davidson MH**, Shurzinske L, Black DM. The Lipid Lowering Effects of Atorvastatin, a New HMG-CoA Reductase Inhibitor: Results of a Randomized, Double-Masked Study. Submitted to *Clinical Therapeutics*, 1996.
22. **Davidson MH**, Dujovne CA, Hunninghake DB, Goldberg RB, Stein EA, Knopp RH, Illingworth DR, Miller VT, Frost PH, Tobert JA. Efficacy of Low Doses of Simvastatin and Niacin Used Concomitantly in Patients with Combined Hyperlipidemia. *Xth International Symposium on Atherosclerosis*. Montreal (Canada), October, 1994.
23. Nawrocki J, Weiss S, Sprecher D, **Davidson MH**, Schwartz S, Lupien P, Jones P, Haber H, Black D. Reduction of LDL-C by More Than 60% With the HMG-CoA Reductase Inhibitor Atorvastatin. *Xth International Symposium on Atherosclerosis*. Montreal (Canada), October, 1994.
24. Bakker-Arkema R, **Davidson MH**, Goldstein R, Davignon J, Isaacsohn J, Weiss S, Keilson L, Brown V, Miller V, Shurzinske L. Atorvastatin, a New HMG-CoA Reductase Inhibitor (HMGR1), is Effective and Safe in Hypertriglyceridemic Patients. *Xth International Symposium on Atherosclerosis*. Montreal (Canada), October, 1994.
25. LaBelle P, **Davidson MH**, Gazdick L, Liss C. Efficacy of Starting Doses of Simvastatin vs Pravastatin in Elderly and Non-Elderly Patients. *Xth International Symposium on Atherosclerosis*. Montreal (Canada), October, 1994.
26. **Davidson MH**, Burns JH, Sugimoto DH, Fuerst F, Drennan KB, Troendle AJ. The Comparative Efficacy of Fluvastatin. A New Synthetic HMG-CoA Reductase Inhibitor in Hyperlipidemic Patients Stratified by Genetic Disorder and Gender. *Xth International Symposium on Drugs Affecting Lipid Metabolism*. Florence (Italy), May, 1992.

27. Harris WS, **Davidson MH**, Dujovne CA, Nash DT, Cefalu WT. For the Promega Study Group: Long-term Safety Of Fish Oil In Hyperlipidemic Patients: A New Synthetic HMG-CoA Reductase Inhibitor in Hyperlipidemic Patients Stratified by Genetic Disorder and Gender. Xth International Symposium on Drugs Affecting Lipid Metabolism. Florence (Italy), May, 1992.
28. **Davidson MH**, Dugan LD, Drennan KB, Story K. Combination Marine Oil & Lovastatin Therapy For Familial Combined Hyperlipidemia. Xth International Symposium on Drugs Affecting Lipid Metabolism. Houston, TX, November, 1989.
29. **Davidson MH**, Subbaiah PV, Segrest JP, Bagdade JD. Cholesterol and Saturated Fat Content of Fish Oil (FO) Preparations Influences the Hypolipidemic Response in Type IV Hyperlipidemic Patients. American College of Cardiology, Annual Meeting. Atlanta, GA, March, 1988.
30. **Davidson MH**. Safety of Omega-3 Fatty Acids. Submitted to the *American Journal of Clinical Nutrition*. National Meeting, Las Vegas, NV, March, 1988.
31. **Davidson MH**, McKenna R, Sullivan DP, Liebson PR, Schoenberger JA, Messer JV. Bleeding Time Prolongation With Marine Oil in Conjunction With Other Anti-Platelet Agents. American College of Cardiology, Annual Meeting. New Orleans, LA, March, 1987.
32. **Davidson MH**. Cholesterol Content of Fish Oil. *NEJM*, [Letter to the Editor]. September, 1987.
33. **Davidson MH**, Liebson PR, Bagdade JD, Messer JV, Schoenberger JA. Marine Lipid Concentrate Reduces Coronary Risk Factors: Double Blind Comparison With Olive Oil. American College of Cardiology, Annual Meeting. Atlanta, GA, March, 1986.
34. **Davidson MH**. Effects of Marine Oil on Blood Lipids. American Academy for the Advancement of Science, Annual Meeting. Philadelphia, PA, May, 1986
35. **Davidson MH**, Subbaiah PV, Bagdade JD. Favorable Changes In The Factors Affecting Reverse Cholesterol Transport After Feeding Marine Lipids To Hypercholesterolemic (HC) Patients. *Circulation* 1986;74:II, 32.
36. **Davidson MH**, Billhardt RA. Acute Ventricular Septal Rupture in Myocardial Infarction: Prognostic Factors for Survival. *Clinical Research* 1985, April.
37. **Davidson MH**, Stang JM. The Clinical Severity of Isolated Disease of the Diagonal Branch Coronary Artery. American Heart Association, National Meeting. Dallas, TX, November, 1981. American College Physicians, Regional Meeting. Dayton, OH, October, 1981.
38. **Davidson MH**, Stang JM. The Efficacy of Floating Telemetry Unit Within an Ambulatory Cardiac Care Unit. AFCR, Midwest Regional Meeting. Chicago, IL; November, 1981. American College Physicians, Regional Meeting. Dayton, OH, October 1981.

CLINICAL RESEARCH EXPERIENCE:

Since 1986, Dr. Michael H. Davidson has served as Principal Investigator in more than 1,000 studies in the following areas:

- Hypercholesterolemia
- Claudication
- Food, Nutrition and Diet
- Heart Failure/Myocardial Infarction
- Hypertension
- Obesity
- Diabetes

- Smoking Cessation
- Osteoporosis

Continuing Medical Education

2001-2007: 50 credit hours/year

Preventive Cardiology Self-Assessment Program: 60 credit hours